Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-versus-Host Disease

Alefacept treatment for refractory chronic extensive GVHD

Abstract

Alefacept (Amevive) is an immunosuppressive dimeric fusion protein that is used for psoriasis control. We recently showed its effect in acute steroid-resistant/dependent GVHD. In this study, we describe the effect of alefacept treatment on chronic extensive GVHD (cGVHD). Twelve patients were included in this study; of these 8 (9 of 13 episodes) showed response. The median time to initial response was 2.25 weeks and the response was marked (n=3), moderate (n=2) or minimal (n=4). In two responding patients, the response was only temporary. Complications that appeared during treatment included infection, pericarditis and squamous cell carcinoma of the lip. All these events may be related to other drugs given simultaneously. With a 30-month median follow-up, 6 of 12 patients are alive, with all but one with stable or improved cGVHD. Six patients died because of GVHD progression, whereas none of the patients experienced relapse of the disease for which the transplantation was done. As reported earlier in psoriatic patients treated with alefacept, we found a consistent increase in the percentage of naive T cells as a consequence of treatment. In conclusion, alefacept is effective for the treatment of cGVHD, and dose and time intervals of treatment should be explored further.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE . An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139: 719–727.

    Article  CAS  PubMed  Google Scholar 

  2. Ellis CN, Krueger GG, Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248–255.

    Article  CAS  PubMed  Google Scholar 

  3. Graves JE, Nunley K, Heffernan MP . Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept. J Am Acad Dermatol 2007; 56: e55–e79.

    Article  PubMed  Google Scholar 

  4. Chamian F, Lin SL, Lee E, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M et al. Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis. J Transl Med 2007; 5: 27–33.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Larsen R, Ryder LP, Svejgaard A, Gniadecki R . Changes in circulating lymphocyte subpopulations following administration of the leucocyte function-associated antigen-3 (LFA-3)/IgG1 fusion protein alefacept. Clin Exp Immunol 2007; 149: 23–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Fraser CJ, Scott Baker K . The management and outcome of chronic graft-versus-host disease. Br J Haematol 2007; 138: 131–145.

    Article  PubMed  Google Scholar 

  7. Shapira MY, Resnick IB, Bitan M, Ackerstein A, Tsirigotis P, Gesundheit B et al. Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report. Bone Marrow Transplant 2005; 36: 1097–1101.

    Article  CAS  PubMed  Google Scholar 

  8. Toor AA, Stiff PJ, Nickoloff BJ, Rodriguez T, Klein JL, Gordon KB . Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity. J Dermatolog Treat 2007; 18: 13–18.

    Article  CAS  PubMed  Google Scholar 

  9. Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006; 12: 252–266.

    Article  PubMed  Google Scholar 

  10. Pugatsch T, Oppenheim A, Slavin S . Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT. Bone Marrow Transplant 1996; 17: 273–275.

    CAS  PubMed  Google Scholar 

  11. Nakamura Y, Leppert O, O'Connel P, Wolff R, Holm T, Culver M et al. Variable number of tandem repeats (VNTR) markers for human gene mapping. Science 1987; 235: 1616–1622.

    Article  CAS  PubMed  Google Scholar 

  12. Atkinson K . Chronic graft-versus-host disease. Bone Marrow Transplant 1990; 5: 69–82.

    CAS  PubMed  Google Scholar 

  13. Deeg HJ, Leisenring W, Storb R, Nims J, Flowers ME, Witherspoon RP et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood 1998; 91: 3637–3645.

    CAS  PubMed  Google Scholar 

  14. Kulkarni S, Powles R, Treleaven J, Riley U, Singhal S, Horton C et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 2000; 95: 3683–3686.

    CAS  PubMed  Google Scholar 

  15. Atkinson K, Horowitz MM, Gale RP, van Bekkum DW, Gluckman E, Good RA et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75: 2459–2464.

    CAS  PubMed  Google Scholar 

  16. Ochs LA, Miller WJ, Filipovich AH, Haake RJ, McGlave PB, Blazar BR et al. Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation. Bone Marrow Transplant 1994; 13: 455–460.

    CAS  PubMed  Google Scholar 

  17. Carlens S, Ringdén O, Remberger M, Lönnqvist B, Hägglund H, Klaesson S et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant 1998; 22: 755–761.

    Article  CAS  PubMed  Google Scholar 

  18. Marks DI, Cullis JO, Ward KN, Lacey S, Syzdlo R, Hughes TP . Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: a comparison of complications in the first 2 years. Ann Intern Med 1993; 119: 207–214.

    Article  CAS  PubMed  Google Scholar 

  19. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH . Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19: 3685–3691.

    Article  CAS  PubMed  Google Scholar 

  20. Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001; 98: 1695–1700.

    Article  CAS  PubMed  Google Scholar 

  21. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J et al. Prevention of graft-versus-host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412–415.

    Article  CAS  PubMed  Google Scholar 

  22. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR et al. A retrospective analysis of therapy for acute graft versus host disease: initial treatment. Blood 1990; 76: 1464–1472.

    CAS  PubMed  Google Scholar 

  23. Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N et al. Treatment of moderate/severe acute graft versus host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024–1030.

    CAS  PubMed  Google Scholar 

  24. Chatenoud L . Monoclonal antibody-based strategies in autoimmunity and transplantation. Methods Mol Med 2005; 109: 297–328.

    CAS  PubMed  Google Scholar 

  25. Zeiser R, Marks R, Bertz H, Finke J . Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies. Ann Hematol 2004; 83: 551–565.

    Article  CAS  PubMed  Google Scholar 

  26. Ghoreschi K, Weigert C, Röcken M . Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol 2007; 25: 574–580.

    Article  PubMed  Google Scholar 

  27. Bashir SJ, Maibach HI . Alefacept (Biogen). Curr Opin Investig Drugs 2001; 2: 631–634.

    CAS  PubMed  Google Scholar 

  28. Chamian F, Lowes MA, Lin SL, Lee E, Kikuchi T, Gilleaudeau P et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci USA 2005; 102: 2075–2080.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Cooper JC, Morgan G, Harding S, Subramanyam M, Majeau GR, Moulder K et al. Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells. Eur J Immunol 2003; 33: 666–675.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Dr Michael Shapira's study is supported by the Dr Sima Lior Fund and by the Zaltzberg Fund.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M Y Shapira.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shapira, M., Abdul-Hai, A., Resnick, I. et al. Alefacept treatment for refractory chronic extensive GVHD. Bone Marrow Transplant 43, 339–343 (2009). https://doi.org/10.1038/bmt.2008.324

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.324

Keywords

This article is cited by

Search

Quick links